Zhuhai Rundu Pharmaceutical Co., Ltd.

002923

CNE1000033G8

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 17/07/2024 am IST			5-day change	1st Jan Change
9.05 ^CNY	-0.44%		-1.42%	-26.66%

09/07	Rundu Pharmaceutical Gets EU Active Pharmaceutical Ingredient Certificate for Antifungal Drug	MT
02/07	Zhuhai Rundu Pharmaceutical Gets Nod for Valsartan Hydrochlorothiazide Tablets	MT

Zhuhai Rundu Pharmaceutical Co., Ltd. has completed an IPO in the amount of CNY 425.25 million.

January 04, 2018 at 10:30 am IST

Zhuhai Rundu Pharmaceutical Co., Ltd. has completed an IPO in the amount of CNY 425.25 million. Security Name: A Shares Security Type: Common Stock Securities Offered: 25,000,000 PriceRange: CNY 17.01 Transaction Features: Sponsor Backed Offering

Latest news about Zhuhai Rundu Pharmaceutical Co., Ltd.

Rundu Pharmaceutical Gets EU Active Pharmaceutical Ingredient Certificate for Antifungal Drug	09/07	MT
Zhuhai Rundu Pharmaceutical Gets Nod for Valsartan Hydrochlorothiazide Tablets	02/07	MT
Rundu Pharmaceutical Probes Allegations of Toxic Food Production	17/06	MT
Zhuhai Rundu Pharmaceutical Co., Ltd. Approves Final Cash Dividend on A Shares for 2023, Payable on 31 May 2024	21/05	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	27/04	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	27/04	CI
Rundu Pharmaceutical's Rabeprazole Sodium Tablets Chosen for China's Centralized Procurement	09/11	MT
Zhuhai Rundu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27/23/27	CI
Zhuhai Rundu Pharma Gets Supplementary Application Approval For Hypertension Drug	26/23/26	MT
Rundu Pharmaceutical Gets Nod to Market Raw Drug Material	13/23/13	MT
Zhuhai Rundu Pharmaceutical Co., Ltd. Approves Final Cash Dividend for 2022, Payable on 31 May 2023	20/23/20	CI
Tianyu Pharmaceutical Unit Gets Approval to Market Hypertension Drug in China	09/23/09	MT
Zhuhai Rundu Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2022	28/23/28	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/23/27	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Approves Management Appointments	16/23/16	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	27/22/27	CI
Rundu Pharmaceutical Unit Wins Drug Production License	04/22/04	MT
Zhuhai Rundu Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2021	13/22/13	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Proposes Cash Dividend for 2021	21/22/21	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	20/22/20	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	19/22/19	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	25/21/25	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Approves Dividend for 2020, Payable on 28 May 2021	20/21/20	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Announces Final Dividend Profit Distribution Proposal for 2020	24/21/24	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Announces to Implement Final Cash Distribution Plan for 2019, Payable on 09 June 2020	03/20/03	CI

Chart Zhuhai Rundu Pharmaceutical Co., Ltd.

Duration

Period

Chart Zhuhai Rundu Pharmaceutical Co., Ltd.

More charts

Company Profile

Zhuhai Rundu Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research, development, manufacture and sales of chemical medicine preparations, chemical medicine raw materials and pharmaceutical intermediates. The Companyâs products cover the fields of cardio-cerebral blood vessels, digestion and anesthesia, among others.

Sector

Pharmaceuticals

Calendar

13/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ZHUHAI RUNDU PHARMACEUTICAL CO., LTD.	-26.66%	419M
ELI LILLY AND COMPANY	+55.35%	848B
NOVO NORDISK A/S	+31.64%	627B
JOHNSON & JOHNSON	-0.10%	363B
MERCK & CO., INC.	+15.47%	318B
ABBVIE INC.	+13.10%	299B
ASTRAZENECA PLC	+15.51%	243B
NOVARTIS AG	+16.72%	225B
AMGEN INC.	+16.54%	179B
PFIZER, INC.	+4.31%	167B